FDA Brief

Warning letters Drugs

FDA warning letter to

TRP Company, Inc

High riskIssued Sep 11, 2023Posted Sep 12, 2023Center for Drug Evaluation and Research | CDER

FDA warns TRP Company that its homeopathic eye drops and ointments are unapproved new drugs and may be adulterated.

What happened

FDA reviewed TRP Company’s website in July 2023 and found its eye products offered for sale with claims to relieve dryness, pink eye, allergies, redness, strain, floaters, twitching, styes, and other eye symptoms. FDA said the products are unapproved new drugs because they are not generally recognized as safe and effective and no approved application is in effect. FDA also said CGMP violations at a contract manufacturer identified in a prior warning letter make TRP’s products adulterated.

What FDA found

  1. The eye products are unapproved new drugs because they are not generally recognized as safe and effective and no FDA-approved application is in effect.

    FD&C Act §505(a), 21 U.S.C. 355(a); §201(p), 21 U.S.C. 321(p)
  2. Selling or shipping these unapproved drugs in interstate commerce is prohibited.

    FD&C Act §§301(d), 505(a), 21 U.S.C. 331(d), 355(a)
  3. Website labeling claims show the products are intended to treat disease or affect body function, making them drugs.

    FD&C Act §201(g)(1), 21 U.S.C. 321(g)(1)
  4. Labeling them as homeopathic does not exempt them from drug approval, adulteration, or misbranding requirements.

    FD&C Act §201(g)(1), 21 U.S.C. 321(g)(1)
  5. The products are adulterated because a contract manufacturer had significant CGMP violations when making TRP’s products.

    FD&C Act §501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  6. Receiving, delivering, or causing shipment of adulterated drugs in interstate commerce is prohibited.

    FD&C Act §§301(a), 301(c), 21 U.S.C. 331(a), 331(c)

What FDA wants

FDA asks TRP to notify it in writing within 15 working days of steps taken to correct violations and prevent recurrence, with supporting documents. If TRP believes the products are not violating the law, it must provide its reasoning and supporting information.

Who should pay attention

  • online sellers and distributors of homeopathic eye drops
  • brands using contract manufacturers for ophthalmic drugs
  • companies making or labeling eye-care drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk